Plain-English translation of NCT05392764 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called empagliflozin to see if it can help patients hospitalized with acute heart failure—a serious condition where the heart cannot pump blood effectively. Researchers will give some patients the medication early during their hospital stay, while others receive a placebo (a pill with no active ingredient), to compare how well the medication works and whether it is safe.
Acute heart failure is a serious condition that can cause fluid to build up in the lungs and body, and patients at high risk need better treatment options. This trial exists to see whether starting this medication early, right when patients arrive at the hospital, can prevent complications and improve their chances of recovery.
You likely qualify if…
You likely don't qualify if…
If you are enrolled, you will be randomly assigned to take either the medication or a placebo pill once daily by mouth. You must be enrolled within 12 hours of arriving at the hospital. The study will follow you during your hospitalization and monitor your heart, kidney function, and overall recovery to see how well the treatment works compared to placebo.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Japan